SynthesisIndian journal of pharmacology2026
Breathing insights: Biomarkers as tools for chronic obstructive pulmonary disease assessment - A systematic review.
Synthesis in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Clinical Perspectives of Biomarkers in Respiratory Diseases: A Narrative Review.Journal of clinical medicine · 2026Review
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Unknotting the crosstalk between COPD and neuroinflammation.Journal of neuroinflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractChronic obstructive pulmonary disease (COPD) remains a major global health burden, posing ongoing challenges in diagnosis and management. This systematic review examines current evidence on biomarkers relevant to COPD, emphasizing their diagnostic, prognostic, and therapeutic potential. A comprehensive search of PubMed and Scopus identified studies published from January 2019 to April 2025 involving adult COPD patients. Two independent reviewers screened observational and randomized studies, with duplicates (n = 24) removed using Mendeley and verified manually. Due to heterogeneity in methodology and outcomes, data were synthesized narratively. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle-Ottawa Scale for observational studies. Traditional biomarkers such as C-reactive protein and fibrinogen were consistently associated with exacerbation risk and disease severity. Interleukins-6 and -8 were elevated in frequent exacerbators, while surfactant proteins showed potential in distinguishing COPD from other chronic lung diseases. Emerging genetic and multiomics markers - such as matrix metalloproteinase-9, chitinase-3-like protein 1, and various microRNAs - demonstrated associations with disease phenotypes and treatment response. The findings highlight that while individual biomarkers offer valuable insights, a combined multimarker approach integrated with clinical parameters may enhance the precision of COPD management. This review provides clinicians and researchers with an updated perspective on the utility and limitations of current biomarkers, supporting the move toward more personalized and effective strategies in COPD care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.